COVID-19 / Coronavirus
Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation
2022-11-03 19:00
1460
The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...
Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19
2022-11-02 08:10
2085
-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...
SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation
2022-11-02 02:00
1802
- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...
Immuno Cure appoints new CFO
2022-11-01 20:18
2579
Strengthening of executive management team to propel growth strategy HONG KONG, Nov. 1, 2022 /PRNewswire/ -- Immuno Cure BioTech, a clinical stage biotechnology group based in the Hong Kong Science Park specialising in DNA vaccines and immunotherapies, announced today the appointment of Mr M...
Karyopharm and Menarini Group Announce Orphan Medicinal Product Designation from the European Commission for Selinexor for the Treatment of Myelofibrosis
2022-11-01 19:40
1985
NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today anno...
Accuray Announces Tomo® C Registration Submission to China's National Medical Products Administration
2022-11-01 19:35
1735
SUNNYVALE, Calif., Nov. 1, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the registration dossier for the CNNC-Accuray joint venture Tomo® C radiation therapy system for the Type B market has been submitted to the Chinese National Medical Products Administration (N...
GenScript Supported Nasal Spray Development for COVID-19 Protection with GMP-grade Antibodies and Subsequently Planned for Long-Term Collaboration with Biogenexis
2022-11-01 11:39
3105
SINGAPORE, Nov. 1, 2022 /PRNewswire/ -- GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a leading global biotechnology company supportedChulalongkorn University, a research-intensive university in Thailand in developing human anti-SARS-CoV-2 antibodies with antibody production a...
EpiVax Joins Intravacc, CEPI on Project to Develop Universal Betacoronavirus Vaccine
2022-10-31 20:00
2656
PROVIDENCE, R.I., Oct. 31, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce participation in a new project with Intravacc, funded by CEPI (Coalition for Epidemic Preparedness Innovations), to develop universal vaccines for betacoronaviruses, including SARS-CoV-2. EpiVax will be...
Senhwa Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer
2022-10-31 19:00
2204
TAIPEI and SAN DIEGO, Oct. 31, 2022 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced today that their first patient has been successfully dosed, in a phase I c...
GC Asia's First Global Chemical Company Retains Number 1 Position in DJSI's Chemicals Business Group for the 4th Consecutive Year
2022-10-28 16:51
2551
BANGKOK, Oct. 28, 2022 /PRNewswire/ -- GC is Asia's First Global Chemical Company to ever be Ranked Number 1 for 4 consecutive years in the Chemicals Business Group by the Dow Jones Sustainability Indices: DJSI. Through business operations that meticulously integrate sustainability with all 3 ESG...
AIA Hong Kong Tops at "Hong Kong Insurance Awards 2022" Scoring the Highest Number of Wins and Snatching Six Grand Awards
2022-10-28 16:29
2592
HONG KONG, Oct. 28, 2022 /PRNewswire/ -- AIA Hong Kong takes pride in the "Hong Kong Insurance Awards 2022" organised by the Hong Kong Federation of Insurers with six Grand Awards and four top-three finalist honours. As the insurer with the highest number of Grand Awards, the awards won by the Co...
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
2022-10-28 11:10
2969
TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...
Life sciences industry's highest achievers celebrated at prestigious Awards ceremony
2022-10-27 22:39
2964
AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards * Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO * Company of the Year: Telix Pharmaceuticals * Emerging Company of the Year: Fusetec AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO a...
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
2022-10-27 21:22
2024
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
Happiness Development Group Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement
2022-10-27 20:00
2603
NANPING, China, Oct. 27, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that on October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") n...
Medtecs to showcase its world-leading PPE solutions in Germany and France
2022-10-27 18:14
881
TAIPEI, Oct. 27, 2022 /PRNewswire/ -- As countries reopen their borders for international travel with global vaccination coverage on the rise, the world is slowly returning to pre-pandemic activity levels since the COVID-19 outbreak nearly 3 years ago. Needless to say, personal protective equi...
Aged care sector turns to financial wellbeing tools to attract staff: Wagestream
2022-10-27 11:04
2823
SYDNEY, Oct. 27 2022 /PRNewswire/ -- Financial wellbeing fintech Wagestream
Ping An Reports Steady Growth of 3.8% in Operating Profit Attributable to Shareholders of Parent Company in 9M 2022
2022-10-26 20:39
3319
HONG KONG and SHANGHAI, Oct. 26, 2022 /PRNewswire/ -- Ping An Insurance (Group) Company ofChina, Ltd. (hereafter "Ping An" or the "Group", HKEx:2318; SSE:601318) today announced its results for the nine months ended30 September 2022. Global capital markets remained volatile in a complex, chall...
Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
2022-10-26 20:10
2219
--ASC10 has two indications: monkeypox and SARS-CoV-2 virus infections. The Investigational New Drug (IND) application of the latter was approved by the U.S. Food and Drug Administration (FDA) inAugust 2022 and Phase Ib clinical trial in COVID-19 patients is underway in the U.S. --Preclinical st...
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
2022-10-26 19:06
3184
Revenue Up 71.9% Year-Over-Year to RMB28,395 Million Net Profit Attributable to Owners of the Company Up 107.1% Year-Over-Year to RMB7,378 Million Diluted Earnings Per Share (EPS) Up 90.1% Year-Over-Year to RMB2.30 Adjusted Non-IFRS Net Profit Attributable to Owners of the Company Up 77.9% Year...
Week's Top Stories
Most Reposted
Troy Animal Healthcare Strengthens Quality Operations with Veeva Vault Quality
[Picked up by 321 media titles]
2024-05-17 07:00Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 319 media titles]
2024-05-15 12:00Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 303 media titles]
2024-05-16 15:00US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39Trip.com Group and Rezdy Join Forces to Offer New Travel Experiences Around the World
[Picked up by 229 media titles]
2024-05-14 18:07Most Read
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
2024-05-15 12:00
8263
Traveloka strengthens sustainability pledge as world's first Platinum Sponsor of GSTC
2024-05-13 16:42
6406
Casio to Release G-SHOCK-Surfrider Foundation Collaboration
2024-05-15 09:00
6139